Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Files Keytruda Plus Chemoradiotherapy for Cervical Cancer in Japan
March 1, 2024
- Otsuka, AN Ventures Hook Up on US$30 Million Investment
February 29, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Towa to Roll Out New WPP Strategy to Maintain NHI Prices of Key Medicines
February 28, 2024
- Takeda to Outsource Dengue Vaccine Production to India’s Biological E
February 28, 2024
- Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
- Radicava’s Brazil Launch Set for February 29: Mitsubishi Tanabe
February 28, 2024
- Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
- Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
- Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- Chugai Tapping Wearable to Objectively Gauge Pain, First Eyes Endometriosis Trial
February 26, 2024
- Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
- Maruho’s China Subsidiary Now Up and Running
February 26, 2024
- Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Astellas CTO Eager to “Democratize” Digital Tools to Boost Productivity
February 21, 2024
- CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…